IL2 and Thrombocytopenia: Toxicities observed included the expected hematologic toxicities of chemotherapy such as neutropenia, thrombocytopenia, and lymphopenia, as well as the transient toxicities of high-dose IL-2 therapy, with two patients who developed pneumocystis pneumonia and one patient who developed Epstein-Barr virus-related lymphoproliferation.